



Staphylococcus— Molecular Pathogenesis, Virulence Regulation and Antibiotics Resistance

Guest Editor:

Prof. Dr. Ewa Szczuka

Department of Microbiology,
Institute of Experimental Biology,
Faculty of Biology, Adam
Mickiewicz University, Poznań,
Uniwersytetu Poznańskiego 6,
61-614 Poznań, Poland

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editor

Staphylococci have attracted recent attention because of their pathogenic potential and their ability to become resistant to antibiotics. In particular, methicillin-resistant *S. aureus* (MRSA) has been extensively studied. Historically associated with hospitals and other healthcare settings, in the last decade, it has also become a frequent cause of infections in the community. The finding that MRSA, as well multidrug-resistant staphylococci, frequently colonize animals, including home pets, has been a reason for concern. The concept of "One Health" clearly recognizes the link between human health and animal health. Microbiome studies are currently underway to determine the composition of staphylococcal species on the skin of animals, including dogs, cats and birds. The question is whether these bacteria can cause diseases in humans. This Special Issue seeks manuscript submissions that will further our understanding of the virulence mechanisms of staphylococci. Submissions that contribute to answering the question of whether methicillin-resistant staphylococci and multidrug-resistant staphylococci occur in domestic and farm animals are especially encouraged.

Prof. Dr. Ewa Szczuka





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)